DepoCyt Benefits - Pacira Pharmaceuticals, Inc.

Sustained release DepoCyt(e) provides physicians with a uniquely convenient once-every-two-week therapy that offers patients the standard care for the treatment of lymphomatous meningitis.

Extends patients' exposure to therapy with sustained release DepoCyt(e):

Increased drug exposure
Decreased dosing frequency
Effective and more convenient dosing regimen
Patients spend less time receiving treatment

Lymphomatous meningitis is a complication of lymphoma that is characterized by the spread of cancer to the central nervous system and the formation of secondary tumors within the thin membranes surrounding the brain. DepoCyt(e) allows physicians the opportunity to fulfill their therapeutic goals for lymphomatous meningitis with more convenient administration.

Stabilizing neurologic status
Maximizing systemic treatment of the primary cancer to prolong survival

DepoCyt(e):
Increased drug exposure
Decreased dosing frequency
Effective and more convenient dosing regimen
Patients spend less time receiving treatment